ArticleJournal of extracellular biology2024
Engineered extracellular vesicles coated with an antimicrobial peptide for advanced control of bacterial sepsis.
Article in Journal of extracellular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- EV-LYSG101: Extracellular Vesicles Loaded With Lysin LYSG101 for Potent Anti-Staphylococcal Activity.Journal of extracellular biology · 2026Article
- Microfluidic Platforms for Exosome Engineering: Scalable Therapeutics for Cancer Immunotherapy and Infectious Diseases.International journal of molecular sciences · 2026Review
- Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Modulation of ESKAPE Bacteria Properties by NK-92 and NK-92-Derived LEVs: First Insights.International journal of molecular sciences · 2026Article
- Clinical Applications of Extracellular Vesicles: Promises and Pitfalls.International journal of molecular sciences · 2026Review
- Biofluid-derived exosomes as next-generation biotherapeutic platforms to combat multidrug-resistant bacterial infections.Regenerative biomaterials · 2026Review
- Engineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections.Research (Washington, D.C.) · 2026Review
- Article
- Cathelicidin LL37-loaded extracellular vesicles from Edwardsiella piscicida promote antibacterial and wound-healing activity.Scientific reports · 2025Article
- Bacterial Extracellular Vesicles and Antimicrobial Peptides: A Synergistic Approach to Overcome Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial Peptide Delivery Systems as Promising Tools Against Resistant Bacterial Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Engineered extracellular vesicles coated with an antimicrobial peptide for advanced control of bacterial sepsis.Journal of extracellular biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alarming sepsis-related mortality rates present significant challenges to healthcare services globally. Despite advances made in the field, there is still an urgent need to develop innovative approaches that could improve survival rates and reduce the overall cost of treatment for sepsis patients. Therefore, this study aimed to develop a novel multifunctional therapeutic agent for advanced control of bacterial sepsis. Extracellular vesicles (EVs) isolated from lipopolysaccharide (LPS) induced HepG2 (hepatocellular carcinoma cells) (iEV) displayed an average particle size of 171.63 ± 2.77 nm, a poly dispersion index (PDI) of 0.32 ± 0.0, and a zeta potential (ZP) of -11.87 ± 0.18 mV. Compared to HepG2 EV, LPS induction significantly increases the EV protein concentration, PDI and ZP, reduces the average size and promotes cell proliferation and cytoprotective effects of the isolated EVs (iEVs) against LPS-induced cytotoxicity. Coating of iEV with a cationic antimicrobial peptide (AMP) to form PC-iEV slightly changed their physical properties and shifted their surface charge toward neutral values. This modification improved the antibacterial activity (2-fold lower minimum bactericidal concentration [MBC] values) and biocompatibility of the conjugated peptide while maintaining iEV cytoprotective and anti-inflammatory activities. Our findings indicate the superior anti-inflammatory and antibacterial dual activity of PC-iEV against pathogens associated with sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.